October 02, 2024

Lupus Nephritis: Key Urinary Biomarkers

A recent study has identified urinary proteins as significant predictors of specific renal lesions in lupus nephritis, offering valuable insights into pathogenic signal pathways. Source: Arthritis & Rheumatology

Conexiant

September 30, 2024

Lupus Treatment Trial Paused Following Patient Deaths

Three of the fatalities showed a common pattern of symptoms and the deaths happened close to the time of dosing, while a non-fatal adverse event showed a similar proximity to dosing.

Reuters

September 27, 2024

Aspirin, Heparin May Boost Outcomes in Recurrent Pregnancy Loss

Low-dose aspirin and/or heparin treatment significantly increased live birth rates to 87.2% in women with recurrent pregnancy loss and anti-β2-glycoprotein I/HLA-DR antibodies, compared to 50.0% without treatment.

Conexiant

September 24, 2024

Lupus Drug Meets Main Goal of Late-Stage Trial

Biogen and UCB's experimental lupus treatment shows promising results in reducing disease activity for lupus patients, offering hope for new therapeutic alternatives in the field.

Reuters

September 20, 2024

Lupus, IBD Share Microbiome Features, Study Shows

Microbiome analysis reveals SLE and IBD share up to 33 common short-chain fatty acid-producing enzymes, suggesting potential shared microbial mechanisms in these distinct autoimmune diseases.

Conexiant

September 13, 2024

Hydroxychloroquine Associated With Lower Cardiovascular Risk in SLE

A recent study suggests that current use of hydroxychloroquine is associated with reduced risk of cardiovascular events in patients with systemic lupus erythematosus.

Conexiant

September 13, 2024

Teclistamab Shows Promise in Treating Refractory Autoimmune Diseases Like SLE in Case Reports

A recent study highlights the potential of teclistamab, a bispecific antibody, in treating refractory systemic lupus erythematosus and other autoimmune diseases, showcasing promising improvements in disease markers and clinical efficacy.

Conexiant

September 09, 2024

Anti-RNAP III Antibodies Linked to Systemic Sclerosis Severity

A recent study reveals potential disease biomarkers in systemic sclerosis patients based on anti-RNA polymerase III antibodies, shedding light on disease activity and progression.

Conexiant

April 29, 2024

A Look Ahead at Rheumatology in 2024

A rheumatologist reflected on rheumatology developments in 2023 and looked ahead to the developments and challenges the field may face in 2024.

Conexiant